an impaired increase in PGE2 in gastric juices which is thought to reflect the amount of PGE2 in the gastric mucosa during steroid treatment in children.3 Moreover, Marino et al have reported that the PGE2 concentration in the gastric secretion in premature infants was significantly lower than that in full term infants.4 On the basis of these findings, we suggest that a decrease or impaired increase in PGE2 in the gastroduodenal mucosa is one of the important factors in the development of gastroduodenal mucosal lesions and perforation in preterm babies treated with dexamethasone.
This suggestion may have a therapeutic implication when it comes to breast feeding, although Ng et al described it in only one of four cases. The administration of oral PGE2 analogues has been shown to protect the gastric mucosa from steroid induced damage. The mechanism by which steroids cause gastrointestinal ulceration is unclear, although it is generally accepted that they reduce the effectiveness of the protective mucosal barrier. In this situation normal acid production may be sufficient to cause gastrointestinal perforation. Since we noted this complication we have tried to reduce acid production, with the H2 receptor antagonist ranitidine, in all babies treated with steroids. To determine the effectiveness of this practice we have been serially monitoring gastric pH in babies treated with dexamethasone and various doses of ranitidine.
We report the effects of using a ranitidine infusion of O 0625 mg/kg/hour in seven babies 
